What Does “FDA-Approved” Actually Mean?

Rethinking Safety and Personalization

For many patients navigating hormone therapy and other personalized treatments, the question of FDA approval can create confusion. You’ve probably heard, “If it’s not FDA approved, it’s not safe.” But is that really true?

Let’s explore the real differences between FDA-approved medications and non-FDA-approved compounded treatments—like bioidentical hormones—so you can make informed decisions about your care.

What Does “FDA-Approved” Actually Mean?

FDA approval is granted to drugs that have gone through the pharmaceutical industry’s formal review process, including:

• Clinical trials funded by the manufacturer

• Review of manufacturing practices and labeling

• Submission of safety and efficacy data to the FDA

But here’s the catch: this process is extremely expensive—often costing over $1–2 billion per drug[^1]. Because of this, it’s usually only large pharmaceutical companies that seek FDA approval, and only for products that can be patented and sold at a profit[^2].

That means:

• Natural substances like bioidentical hormones cannot be patented in their pure form.

• Therefore, they are rarely submitted for FDA approval, even if they are effective and widely used.

• FDA approval is often more about business strategy than universal safety.

  
  

Are FDA-Approved Drugs Always Safe?

No—and in fact, many drugs that received FDA approval were later pulled from the market due to serious safety concerns. Consider these facts:

• Between 1997 and 2019, nearly one-third of FDA-approved drugs had safety issues identified after approval[^3].

• Some high-profile examples include Vioxx, Propulsid, and Fen-Phen, all of which were FDA approved—and later withdrawn due to severe or fatal side effects[^4].

In short, FDA approval does not guarantee safety. It means a drug passed initial review, not that long-term risks are fully understood.

What About Compounded Bioidentical Hormones?

Compounded bioidentical hormones are custom-made medications created by licensed pharmacies to match a patient’s exact hormonal needs. While they are not FDA-approved in the commercial drug sense, they are:

• Made using FDA-registered active pharmaceutical ingredients (APIs)[^5]

• Regulated by state pharmacy boards and/or the FDA depending on whether they are 503A or 503B pharmacies[^6]

• Subject to USP compounding standards, including sterility, potency, and purity testing[^7]

Bioidentical hormones used in compounding—such as estradiol, progesterone, and testosterone—are chemically identical to the hormones naturally produced by your body. They’ve been used safely for decades in Europe and the U.S., and clinical organizations like the North American Menopause Society acknowledge their clinical role[^8].

Why Non-FDA-Approved Doesn’t Mean “Unsafe”

Here’s what’s important to understand:

• FDA approval is a regulatory status, not a safety guarantee.

• Many natural, non-patented, and bioidentical substances are excluded from FDA review simply because there’s no financial incentive for large companies to fund approval trials.

• Meanwhile, compounded medications are individually tailored, tested, and monitored in real time—often making them safer for individual patients, especially those with allergies, sensitivities, or complex needs[^5][^6].

  
  

Final Thoughts : Personalized Medicine Deserves a Personalized Lens

If you're working with a hormone optimization clinic that uses trusted compounding pharmacies, you're not “settling” for non-FDA-approved care—you’re choosing customization, transparency, and safety tailored to you.

FDA approval has a place, but it's not the only marker of quality. For patients needing bioidentical hormone replacement therapy, compounded medications may offer a safer, more effective solution than mass-produced, synthetic drugs approved for the masses.

Works Cited (MLA Style)

1. DiMasi, Joseph A., et al. “Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs.” Journal of Health Economics, vol. 47, 2016, pp. 20–33. https://doi.org/10.1016/j.jhealeco.2016.01.012

2. Light, Donald W., and Rebecca Warburton. “Demythologizing the High Costs of Pharmaceutical Research.” BioSocieties, vol. 6, no. 1, 2011, pp. 34–50. https://doi.org/10.1057/biosoc.2010.40

3. Downing, Nicholas S., et al. “Postmarket Safety Events Among Novel Therapeutics Approved by the US FDA Between 2001 and 2010.” JAMA, vol. 317, no. 18, 2017, pp. 1854–63. https://doi.org/10.1001/jama.2017.5150

4. U.S. Food and Drug Administration. “Drug Safety and Availability.” https://www.fda.gov/drugs/drug-safety-and-availability

5. U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.” https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

6. U.S. Food and Drug Administration. “Outsourcing Facilities (503B) and Compounding Pharmacies (503A).” https://www.fda.gov/drugs/human-drug-compounding/outsourcing-facilities

7. United States Pharmacopeia. “USP Compounding Standards.” https://www.usp.org/compounding

8. North American Menopause Society. “The 2017 Hormone Therapy Position Statement of The North American Menopause Society.” Menopause, vol. 24, no. 7, 2017, pp. 728–753. https://doi.org/10.1097/GME.0000000000000921